NEW YORK, April 13, 2010 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder (MDD).
